CCO Management Series
When to Start, What to Use: A Master Class in the Use of First-Line Antiretroviral Therapy
Timing of Antiretroviral Initiation in Treatment-Naive Patients |
Module 1 of 3 |
|
|
|
Keith Henry, MD, discusses how the December 2007 update of the DHHS guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents may affect clinical practice regarding when to initiate antiretroviral therapy in treatment-naive patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the current DHHS recommendations on when to start antiretroviral therapy in treatment-naive HIV-infected individuals
- Describe data from observational cohorts that have suggested benefits to initiating therapy at CD4+ cell counts > 350 cells/mm3
- Discuss the potential risks and benefits of earlier initiation of antiretroviral therapy
|
Clinical Trials of Antiretroviral Therapy in Treatment-Naive Patients |
Module 2 of 3 |
- Marshall J. Glesby, MD, PhD
|
|
|
Marshall J. Glesby, MD, PhD, discusses the results from the latest clinical trials on antiretroviral therapy options for the management of treatment-naive patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- List current antiretroviral drugs recommended for treatment-naive HIV-infected individuals
- Discuss clinical trial data concerning first-line therapy in HIV-infected patients
- Describe findings from studies investigating novel antiretroviral drug classes in treatment-naive patients
|
Antiretroviral Selection in Treatment-Naive Patients |
Module 3 of 3 |
|
|
|
Paul E. Sax, MD, reviews data concerning the use of current antiretroviral drugs and novel therapies to outline optimal management strategies for treatment-naive patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the recommended antiretroviral regimens for antiretroviral-naive, HIV-infected individuals as outlined in treatment guidelines
- Discuss clinical trial data and host factors that are important to consider when choosing an initial regimen
- Evaluate treatment strategies for the management of antiretroviral-naive patients
|
Interactive Case Challenges
When to Initiate Therapy in a Patient Recently Diagnosed With HIV
|
|
|
Along with Keith Henry, MD, determine when to start antiretroviral therapy in a recently HIV-infected and treatment-naive patient based on the updated DHHS treatment guidelines released in December 2007.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the current DHHS recommendations on when to start antiretroviral therapy in treatment-naive HIV-infected individuals
- Describe data from observational cohorts that have suggested benefits to initiating therapy at CD4+ cell counts > 350 cells/mm3
- Discuss the potential risks and benefits of earlier initiation of antiretroviral therapy
|
Management of an HIV-Infected Treatment-Naive Diabetic Female With Dyslipidemia
- Marshall J. Glesby, MD, PhD
|
|
|
Along with Marshall J. Glesby, MD, PhD, choose the optimal management strategies for a treatment-naive HIV-infected diabetic female with dyslipidemia.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Define the effects of various NRTIs on fasting triglyceride levels
- Discuss the occurrence of renal toxicity in patients receiving tenofovir
- Describe the impact of HIV infection on bone mineral density
|
Treatment Considerations in an HIV-Infected Patient With Ongoing Methamphetamine Use
|
|
|
Along with Paul E. Sax, MD, choose the optimal management strategies for a HIV-infected, treatment-naive patient with ongoing substance abuse based on the updated DHHS treatment guidelines released in December 2007.
Learning Objectives
Upon completion of this activity, participants should be able to:
- List the US Food and Drug Administration–approved antiretroviral regimens that are administered once daily
- Indicate the US Department of Health and Human Services’ recommended time for initiating antiretroviral therapy
- Describe strategies for selecting individualized first-line antiretroviral therapy
|
Interactive Tool
Choosing First-Line Antiretroviral Therapy
|
|
Considering the efficacy, safety, and tolerability factors in determining the appropriate antiretroviral components for your patient’s initial HAART regimen?
This tool enables you to review data from controlled studies on the DHHS and IAS-USA preferred antiretroviral regimens for initial antiretroviral therapy. You can also view a convenient graphical summary of the key data from those studies and print the data and/or download corresponding slides.
Format: Adobe Flash (.swf)
| File size: 140 KB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|